4.6 Article

Expanding the Clinical Phenotype of SNCA Duplication Carriers

期刊

MOVEMENT DISORDERS
卷 24, 期 12, 页码 1811-1819

出版社

WILEY
DOI: 10.1002/mds.22682

关键词

Parkinson's disease; SNCA duplication; PET; dementia; reduced penetrance

资金

  1. MEXT of Japan [20023028]
  2. Grants-in-Aid for Scientific Research [20023028] Funding Source: KAKEN

向作者/读者索取更多资源

SNCA duplication is a recognized cause of familial Parkinson's disease (PD). We aimed to explore the genetic and clinical variability in the disease manifestation. Molecular characterization was performed using real-time PCR, SNP arrays, and haplotype analysis. We further Studied those patients who were found to harbor SNCA duplication with olfactory function tests. polysomnography, and PET. We identified four new families and one sporadic patient with SNCA duplication. Eleven symptomatic patients from these four families presented with parkinsonism, of which three subsequently developed dementia. The lifetime estimate of overall penetrance was 43.8%. FDG-PET study of symptomatic patients showed hypometabolism in the occipital lobe, whereas asymptomatic carriers of SNCA duplication demonstrated normal glucose metabolism. Symptomatic patients showed abnormal olfactory function and polysomnography and asymptomatic carriers showed normal results. The clinical features of SNCA duplication include parkinsonism with or Without dementia. Asymptomatic carriers displayed normal test results with the eldest individual aged 79 years; thus, even a carrier of SNCA duplication may escape the development of PD. This difference in age-associated penetrance may be due to the genetic background or environmental exposures. Further studies of SNCA duplication carriers will help identify discase-modifiers and may open novel avenues for future treatment. (C) 2009 Movement Disorder Society

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据